Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection. At the American Society of Retina Specialists annual meeting, Eric W. Schneider, MD, presented study data examining the baseline characteristics that could predict catastrophic vision loss after the development of subretinal hemorrhage following anti-VEGF treatment. “There was no association seen with anticoagulant or antiplatelet use, systemic hypertension or evidence of